Magnetic resonance imaging-derived parameters to predict response to regorafenib in recurrent glioblastoma-Reference-Cited by-同舟云学术

Magnetic resonance imaging-derived parameters to predict response to regorafenib in recurrent glioblastoma

Published:2023-05-29 Issue:10 Volume:65 Page:1439-1445
ISSN:0028-3940
Container-title:Neuroradiology
language:en
Short-container-title:Neuroradiology

Author:

Martucci Matia^ORCID,Ferranti Andrea Maurizio,Schimperna Francesco,Infante Amato,Magnani Francesca,Olivi Alessandro,D’Alessandris Quintino Giorgio,Gessi Marco,Chiesa Silvia,Mazzarella Ciro,Russo Rosellina,Giordano Carolina,Gaudino Simona

Publisher

Springer Science and Business Media LLC

Subject

Cardiology and Cardiovascular Medicine,Neurology (clinical),Radiology, Nuclear Medicine and imaging

Link

https://link.springer.com/content/pdf/10.1007/s00234-023-03169-y.pdf

Reference28 articles.

1. Stupp R, Mason WP, van den Bent MJ et al (2005) Radiotherapy plus concomitant and adjuvant temozolomide for glioblastoma. N Engl J Med 352:987–996. https://doi.org/10.1056/NEJMoa043330

2. Birzu C, French P, Caccese M et al (2020) Recurrent glioblastoma: from molecular landscape to new treatment perspectives. Cancers (Basel) 13:47. https://doi.org/10.3390/cancers13010047

3. Calabrese C, Poppleton H, Kocak M et al (2007) A perivascular niche for brain tumor stem cells. Cancer Cell 11:69–82. https://doi.org/10.1016/j.ccr.2006.11.020

4. Chen J, Li Y, Yu TS et al (2012) A restricted cell population propagates glioblastoma growth after chemotherapy. Nature 488:522–526. https://doi.org/10.1038/nature11287

5. Bao S, Wu Q, McLendon RE et al (2006) Glioma stem cells promote radioresistance by preferential activation of the DNA damage response. Nature 444:756–760. https://doi.org/10.1038/nature05236

Cited by 3 articles. 订阅此论文施引文献订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献

1. MR-Parameter könnten Therapieansprechen bei Glioblastom-Rezidiv abschätzen;Neuroradiologie Scan;2024-07

2. Unlocking Hope: Anti-VEGFR inhibitors and their potential in glioblastoma treatment;Critical Reviews in Oncology/Hematology;2024-06

3. REGOMA-OSS: a large, Italian, multicenter, prospective, observational study evaluating the efficacy and safety of regorafenib in patients with recurrent glioblastoma;ESMO Open;2024-04